7. Revenue


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2018		2019		2018		2019
Product revenue, net	$	—	$	1,445	$	—	$	1,445
Collaboration revenues		—		5,051		6,500		6,051
Research premium		427		424		1,907		1,168
Government grants		34		—		452		484
Total	$	461	$	6,920	$	8,859	$	9,148

The three and nine month period ended September 30, 2019 includes $5.0 million of collaboration revenues recorded from the Sinovant License Agreement (See Note 11) related to a milestone payment that became due upon receipt of FDA approval for XENLETA. The nine month period ended September 30, 2019, includes an upfront payment of $1.0 million under the Sunovion License Agreement that was received in April 2019. Product revenue, net, relate to sales of XENLETA. The collaboration revenues for the nine months ended September 30, 2018 reflect the income recorded from the Sinovant License Agreement and included a $5.0 million non-refundable upfront payment received in the first quarter of 2018 as consideration for entering into the Sinovant License Agreement (see Note 11) as well as $1.5 million of variable consideration related a future milestone payment that the Company believed was probable to be met which was received in February 2019.